Skip to content
Screener

Jazz Pharmaceuticals JAZZ Zepzelca — Revenue from Contract with Customer, Excluding Assessed Tax

Other product segments

Xywav
$408.2M+18.4%
Epidiolex/Epidyolex
$249.8M+14.7%
Rylaze/Enrylaze
$103.7M+10.1%
Defitelio/defibrotide
$47.4M+16.5%
Modeyso
$41.4M—
High-sodium oxybate AG royalty revenue
$36.3M-25.8%
Xyrem
$31.2M-16.1%
Vyxeos
$26.6M-9.8%
Ziihera
$13.3M+565%
Other royalty and contract revenues
$9.76M+27.5%
Other
$2.7M-73.8%

Similar metrics at other companies

Entergy logo
ETROther revenues — Revenue from Contract with Customer, Excluding Assessed Tax
$36.28M-41.5%
CarMax logo
KMXService revenues — Revenue from Contract with Customer, Excluding Assessed Tax
$24.2M+24.1%
Travel + Leisure logo
TNLAncillary Revenues — Revenue from Contract with Customer, Excluding Assessed Tax
$0-100%
Travel + Leisure logo
TNLTransaction Revenues — Revenue from Contract with Customer, Excluding Assessed Tax
$109M-6.8%
Restaurant Brands International logo
QSRProperty revenues — Revenue from Contract with Customer, Excluding Assessed Tax
$0-100%
Northern Trust logo
NTRSOther — Revenue from Contract with Customer, Excluding Assessed Tax
$68.6M+8.2%

Other financials

Income statement

See full
Revenue$1.1B+19.1%
Operating income$336.6M+702%
Net income$293.1M+417%
EPS (diluted)$4.43+391%

Balance sheet

See full
Cash & equivalents$667.5M-64.1%
Total debt$5.4B-0.1%
Total equity$4.5B+8.6%
Total assets$11.9B+2.8%

Cash flow

See full
Operating cash flow$408.2M-5.0%
CapEx$19.7M+41.7%
Free cash flow$388.5M-6.6%

Valuation

See full
Market cap$16.98B+165%
Enterprise value$21.71B+104%
P/S3.8×+2.3×

Profitability

See full
Operating margin-11.9%-28.1pp
Net margin-8.9%-20.5pp
FCF margin28.6%-8.6pp

Returns & leverage

See full
Return on equity-9.1%-21.2pp
Debt / equity1.2×-0.1×
Current ratio2×-1.3×

Where this comes from

Reported directly by Jazz Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026.

Filed
May 5, 2026, 4:09 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001232524-26-000025
Line itemThree Months Ended March 31, 20262025
Epidiolex/Epidyolex249.8217.7
Epilepsy249.8217.7
Rylaze/Enrylaze103.794.2
Zepzelca101.063.0
Defitelio/defibrotide47.440.7
Modeyso41.4—
Vyxeos26.629.5
Ziihera13.32.0

Item 1.Financial Statements

FAQ

What is Jazz Pharmaceuticals's zepzelca — revenue from contract with customer, excluding assessed tax?
Jazz Pharmaceuticals (JAZZ) reported zepzelca — revenue from contract with customer, excluding assessed tax of $101M in Q1 2026.
How has Jazz Pharmaceuticals's zepzelca — revenue from contract with customer, excluding assessed tax changed year-over-year?
Jazz Pharmaceuticals's zepzelca — revenue from contract with customer, excluding assessed tax increased by 60.3% year-over-year, from $63M to $101M.
What is the long-term trend for Jazz Pharmaceuticals's zepzelca — revenue from contract with customer, excluding assessed tax?
Over 4 years (2021 to 2025), Jazz Pharmaceuticals's zepzelca — revenue from contract with customer, excluding assessed tax has grown at a 5.6% compound annual growth rate (CAGR), from $246.81M to $307.28M.
What does zepzelca — revenue from contract with customer, excluding assessed tax mean?
This metric represents the total net revenue generated from the sale of the oncology product Zepzelca, excluding any sales-based taxes. It reflects the commercial performance and market adoption of this specific therapeutic agent within the company's oncology portfolio. This figure is a key indicator of the product's lifecycle stage and its contribution to the firm's overall top-line growth.

Ask your AI about Jazz Pharmaceuticals's zepzelca — revenue from contract with customer, excluding assessed tax.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude